Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Adds Two More PhRMA Lobbyists To D.C. Office

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen’s lobbying team will include PhRMA’s point person on FDA legislation (Mara Guarducci) and Medicare/reimbursement specialist (Scott Olsen). Both will report to Amgen’s newly named VP-Government Affairs Rodger Currie.
Advertisement

Related Content

Amgen D.C. Office Adds Two More PhRMA Lobbyists
Amgen D.C. Office Adds Two More PhRMA Lobbyists
PhRMA Makes It Official: Rep. Tauzin Takes Over As CEO Jan. 3
PhRMA Makes It Official: Rep. Tauzin Takes Over As CEO Jan. 3
Amgen Creates New VP Post For Reimbursement & Payment Policy
Amgen Creates New VP Post For Reimbursement & Payment Policy
PhRMA Federal Affairs Group Adds Two Former Hill Staffers
PhRMA Federal Affairs Group Adds Two Former Hill Staffers
PhRMA Chief Lobbyist Currie Will Head Amgen D.C. Office
PhRMA Chief Lobbyist Currie Will Head Amgen D.C. Office

Topics

Advertisement
UsernamePublicRestriction

Register

PS059085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel